Výsledky vyhledávání - "Solveig G. Ericson"

Industry's Giant Leap Into Cellular Therapy: Catalyzing Chimeric Antigen Receptor T Cell (CAR-T) Immunotherapy

Autor: Manisha Patel, Lamis K. Eldjerou, Stacie Ittershagen, Tetiana Taran, Charlene Hall, Florence Salmon, Deborah Roccoberton, Miriam Fuchs, Vadim V. Romanov, Oezlem Anak, Ali Shojaee, Solveig G. Ericson, Mimi Leung, David Lebwohl, Eric Bleickardt

Publikováno v: Current hematologic malignancy reports. 14(1)

We describe the significant technological leap from bench to bedside that was achieved through a strong academic-industry collaboration between dedicated clinicians and researchers at the University of Pennsylvania, the Children’s Hospital of Phila

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b91216bb85d11bcf8219128ced23b2fe
https://pubmed.ncbi.nlm.nih.gov/30666506

Zobrazit plný text záznamu

Exploratory study on the impact of switching to nilotinib in 18 patients with chronic myeloid leukemia in chronic phase with suboptimal response to imatinib

Autor: Jerald P. Radich, Solveig G. Ericson, Daniel J. DeAngelo, Carole B. Miller, Ghulam Warsi, Felice P. Lin, Sikander Ailawadhi, Luke P. Akard, Anand Jillella

Publikováno v: Therapeutic Advances in Hematology. 8:3-12

Background: The phase II, exploratory, open-label Exploring Nilotinib BCR-ABL Effects (ENABL) study [ ClinicalTrials.gov identifier: NCT00644878] assessed the impact of switching to nilotinib therapy in patients with chronic myeloid leukemia in chron

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a887ed9c7737007000945f1d39a9d97d
https://doi.org/10.1177/2040620716678118

Zobrazit plný text záznamu

Assessment of treatment and monitoring patterns and subsequent outcomes among patients with chronic myeloid leukemia treated with imatinib in a community setting

Autor: Mansoor N. Saleh, Lei Chen, Kavita R. Sail, Sally Haislip, Tamara Hess, James H. Jackson, Solveig G. Ericson, James Gilmore, Joyce Sharpe

Publikováno v: Current Medical Research and Opinion. 30:529-536

Real-world treatment and monitoring patterns have not been well documented among imatinib-treated chronic phase chronic myeloid leukemia (CP-CML) patients. Thus, we evaluated these patterns and responses to imatinib in CP-CML patients.This retrospect

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::03ed4ded6418f387fcae346ea57aab9e
https://doi.org/10.1185/03007995.2013.858621

Zobrazit plný text záznamu

Monitoring and switching patterns of patients with chronic myeloid leukemia treated with imatinib in community settings: a chart review analysis

Autor: Solveig G. Ericson, Eric Q. Wu, Jipan Xie, Elias Jabbour, Lei Chen, Annie Guerin, Andrew P. Yu

Publikováno v: Current Medical Research and Opinion. 28:1831-1839

Monitoring treatment response is an integral part of chronic myeloid leukemia (CML) treatment. The guidelines recommend regular monitoring using standard methods (e.g., real-time quantitative polymerase chain reaction based on the international scale

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00b6c9468cc13d7fd8a64c4ebbf06867
https://doi.org/10.1185/03007995.2012.741577

Zobrazit plný text záznamu

Final 5-year results of Z-FAST trial

Autor: Edith A. Perez, Ghulam Warsi, J. Thaddeus Beck, Charles L. Vogel, John Hohneker, Linda D. Bosserman, W. Graydon Harker, Eliza Argonza-Aviles, Christopher Seidler, Solveig G. Ericson, Adam Brufsky, Lixian Jin

Publikováno v: Cancer. 118:1192-1201

BACKGROUND: Postmenopausal breast cancer (BC) patients receiving adjuvant aromatase inhibitor therapy are at risk of progressive bone loss and fractures. Zoledronic acid inhibits osteoclastic bone resorption, is effective in maintaining bone health,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::72bac04e2ade3e47ea5f0cad4c06c72c
https://doi.org/10.1002/cncr.26313

Zobrazit plný text záznamu

Results of a Multicenter Open-Label Randomized Trial Evaluating Infusion Duration of Zoledronic Acid in Multiple Myeloma Patients (the ZMAX Trial)

Autor: Ralph V. Boccia, Timothy Lopez, James R. Berenson, Ghulam Warsi, Simone Lake, Solveig G. Ericson, Eliza Argonza-Aviles, Robert H. Collins

Publikováno v: The Journal of Supportive Oncology. 9:32-40

Zoledronic acid, an intravenous (IV) bisphosphonate, is a standard treatment for multiple myeloma (MM) but may exacerbate preexisting renal dysfunction. The incidence of zoledronic acid-induced renal dysfunction may correlate with infusion duration.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ef73deb23579c6177fa10aa88bcd0a57
https://doi.org/10.1016/j.suponc.2010.12.002

Zobrazit plný text záznamu

Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Receiving Tisagenlecleucel Treatment in the JULIET Study

Autor: Vadim V. Romanov, Stephen J. Schuster, Solveig G. Ericson, David G. Maloney, James Signorovitch, Richard T. Maziarz, Frederick L. Locke, Elisha S. Rusch

Publikováno v: Blood. 132:4183-4183

Introduction: CAR-T cell therapy has demonstrated prompt and durable clinical responses in patients with r/r DLBCL, but is associated with unique toxicities such as cytokine-release syndrome (CRS) and neurotoxicity (NT). NT is the second most common

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8c5b2c840cb270fd57f6cf87d31c7756
https://doi.org/10.1182/blood-2018-99-118595

Zobrazit plný text záznamu

Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study

Autor: Solveig G. Ericson, Elisha S. Rusch, David G. Maloney, Richard T. Maziarz, Frederick L. Locke, Vadim V. Romanov, James Signorovitch, Stephen J. Schuster

Publikováno v: Blood. 132:4190-4190

Introduction: Autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy achieves rapid and durable responses in patients with r/r DLBCL, although unique potential toxicities require specialized management. Cytokine release syndrome (CRS) is

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9954669126b31a6b4c7a542b6a96e6e4
https://doi.org/10.1182/blood-2018-99-113052

Zobrazit plný text záznamu

Zoledronic Acid Effectively Prevents Aromatase Inhibitor–Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole: Z-FAST Study 36-Month Follow-up Results

Autor: Edith A. Perez, Ghulam Warsi, Richard R. Caradonna, Halle C. F. Moore, C. Michael Jones, Lixian Jin, Adam Brufsky, Solveig G. Ericson, Linda D. Bosserman, Barbara Haley

Publikováno v: Clinical Breast Cancer. 9:77-85

Postmenopausal women with breast cancer receiving adjuvant aromatase inhibitors (AIs) are at risk for accelerated bone loss and subsequent fractures. The ongoing Zometa-Femara Adjuvant Synergy Trial (Z-FAST) is evaluating the efficacy and safety of z

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::53530b775224827137ca8fb70dd4afab
https://doi.org/10.3816/cbc.2009.n.015

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání